Neurogene Inc. Increase (Decrease) in Accounts Payable
Neurogene Inc. (NGNE) reported Increase (Decrease) in Accounts Payable of $1.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Neurogene Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.12M.
- Neurogene Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.42M, a 42.98% increase year-over-year.
- Neurogene Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $409.00K.
- Neurogene Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$501.00K.
- Neurogene Inc. increase (decrease) in accounts payable for fiscal 2025 was $627.00K.
- Neurogene Inc. increase (decrease) in accounts payable for fiscal 2024 was -$77.00K, a 111.54% decline from fiscal 2023.
- Neurogene Inc. increase (decrease) in accounts payable for fiscal 2023 was $667.00K.
- Neurogene Inc. increase (decrease) in accounts payable for fiscal 2022 was -$3.61M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.30M 10-Q · filed 2026-08-11 | $1.71M derived: sum of 3 quarters · filed 2026-08-11 | $1.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.42M 10-Q · filed 2026-05-12 | $2.83M derived: sum of 2 quarters · filed 2026-05-12 | $2.33M derived: sum of 3 quarters · filed 2026-05-12 | $1.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$92.00K derived: sum of 2 quarters · filed 2026-03-24 | -$1.07M derived: sum of 3 quarters · filed 2026-08-11 | $627.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | -$501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.48M derived: sum of 2 quarters · filed 2026-08-11 | $218.00K 10-Q · filed 2025-11-13 | -$198.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$975.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $719.00K 10-Q · filed 2026-08-11 | $303.00K derived: sum of 3 quarters · filed 2026-08-11 | $274.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-12 | $1.28M derived: sum of 2 quarters · filed 2026-05-12 | $1.25M derived: sum of 3 quarters · filed 2026-05-12 | $1.48M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$445.00K derived: sum of 2 quarters · filed 2026-03-24 | -$212.00K derived: sum of 3 quarters · filed 2026-03-24 | -$77.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | -$29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $204.00K derived: sum of 2 quarters · filed 2025-11-13 | $339.00K 10-Q · filed 2025-11-13 | -$503.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $233.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $368.00K 10-Q · filed 2025-08-11 | -$474.00K derived: sum of 3 quarters · filed 2025-08-11 | $183.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $135.00K 10-Q · filed 2025-05-09 | -$707.00K derived: sum of 2 quarters · filed 2025-05-09 | -$50.00K derived: sum of 3 quarters · filed 2025-05-09 | -$23.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$842.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$185.00K derived: sum of 2 quarters · filed 2025-03-24 | -$158.00K derived: sum of 3 quarters · filed 2025-03-24 | $667.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $657.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $684.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.51M 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $852.00K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $825.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$3.61M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |